Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06633354
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-08
Brief Title:
Targeting CD5 CAR-T Cells in the Treatment of rr CD5 T-ALL
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Clinical Study on the Safety and Effectiveness of Targeting CD5 CAR-T Cells in the Treatment of rr CD5 T-ALL
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Clinical Study on the Safety and Effectiveness of targeting CD5 CAR-T Cells in the treatment of rr CD5 T-ALL
Detailed Description:
In this study 30 patients with relapsed refractory T-ALL were proposed to undergo CD5 CAR-T Cells therapy Under the premise that its safety has been clarified in previous studies further observation and evaluation of the effectiveness of CD5 CAR-T Cells therapy for relapsed refractory T-ALL At the same time on the basis of expanding the sample size more safety data on CD5 CAR-T Cells treatment for relapsed refractory T-ALL were accumulated
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None